POST 23rd_BEF
> ATTENDEES​​
> INVESTORS​
> PRESENTERS
​​> EXHIBITORS​​
> SPONSORS​​
> SUPPORTERS​​

IN-PERSON PRESENTERS:

20-minute presenters

Adiso Therapeutics, Inc.

Adiso is a clinical-stage biopharmaceutical company dedicated to improving the health of patients suffering from debilitating inflammatory diseases. This dedication is epitomized by our lead clinical candidates, ADS051, an oral gut-restricted modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis; and ADS032, a dual NLRP3/NLRP1 inflammasome inhibitor initially being developed for inflammatory diseases of the lung, additionally ADS024, an oral single strain live biotherapeutic product (LBP) mild-to-moderate ulcerative colitis and prevention of C. difficile recurrence. Adiso has built these development programs upon a rich history of institutional and academic collaboration, including the University of Massachusetts Chan Medical School, the Hudson Institute of Medical Sciences Centre for Innate Immunity and Infectious Diseases in Australia, the University of Edinburgh Centre for Inflammation Research and the University College Cork, Ireland, the APC Microbiome Institute.​

adisotx.com/

AM-Pharma B.V.

AM-Pharma, founded in 2001 and based in Utrecht, the Netherlands, is developing its proprietary recombinant human alkaline phosphatase therapeutic, ilofotase alfa, for treatment of acute on chronic kidney injury and the rare disease hypophosphatasia.

www.am-pharma.com/

ARMGO Pharma, Inc.

First-in-Class Disease-Modifying Therapeutics in Cardiac and Skeletal Muscle Diseases.​

www.armgo.com/

Azafaros B.V.

Founded in 2018, Azafaros is a clinical-stage biotech company working on building a pipeline of disease-modifying therapeutics to offer new treatment options to patients with lysosomal storage disorders, including GM1 and GM2 Gangliosidoses and Niemann-Pick disease type C.​

www.azafaros.com/

Domain Therapeutics SA

Immune checkpoint inhibitors (ICIs) has significantly changed the landscape in oncology, but this groundbreaking progress is a reality for only a limited fraction of patients.  What about the others? What about the vast majority of non-responders?

Domain is the only one company fully dedicated to exploit the unique potential of GPCR in immuno-oncology.
​
Domain Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative treatments for immuno-oncology to bring solution to patients who do not response to ICI treatment.

Backed to 20 years of expertise in GPCR drug discovery and delivery, the company pioneers the huge and unveiled potential of GPCRs in immunosuppression to deliver game changing treatments abled to reverse immunosuppression mediated by the membrane receptors.

Its pipeline is made of:
• A2a/A2b antagonist (M1069) - small molecule candidate in partnership with Merck KGaA - Phase I ascending dose study ongoing
• EP4 receptor antagonist (DT-9081) - small molecule candidate - Phase I ascending dose study dosing ongoing
• Anti-CCR8 antibody (DT-7012) - monoclonal antibody candidate - Phase I study to commence by mid-2025
• PAR2 NAM antagonist (DT-9045) - small molecule candidate - Phase I study to commence by mid-2025

The company positions each asset in the right indication, the right subpopulation of patients and with the right combo to reach the optimal benefit and success rate in the clinic and bring solution to cancer patients.

Domain exploits a differentiating cross validated approach to identify GPCRs specifically expressed in tumor infiltrates and involved in immunosuppression.

Domain is the partner of choice to discover, launch and bring to the clinic immunotherapies to bypass immunosuppression responsible of clinical failure of immune checkpoint inhibitors and turning tumors into non-responding status.

www.domaintherapeutics.com

GeNeuro SA
[EPA: GNRO]

GeNeuro is a Swiss-based clinical stage company committed to bringing safe and effective solutions for stopping the progression of neurodegenerative diseases, such as Multiple Sclerosis (MS), Post-COVID (PASC) and Amyotrophic Lateral Sclerosis (ALS).​

www.geneuro.com

IAMA Therapeutics S.r.l.

IAMA Therapeutics pushes the boundaries of neuroscience drug discovery to develop new therapeutic opportunities and make a difference in children affected by epilepsy, neurodevelopmental and cognitive disorders. IAMA Therapeutics is developing IAMA-6 for potentially treating drug-resistant epilepsies and rare syndromic forms of autism, in addition to chloride modulators targeting neuropsychiatric conditions characterized by cognitive impairment.

www.iamatherapeutics.com/

Oryzon Genomics, S.A.
[BME: ORY​]

A public clinical-stage biopharma developing epigenetics for CNS disorders and Oncology. +50 highly-qualified professionals located in Barcelona, Boston, NYC and San Diego. Listed in Spain, aiming at NASDAQ-listing.

Two uncorrelated Phase II compounds: iadademstat (oncology) and vafidemstat (CNS).

Iadademstat, a best-in-class LSD1 inhibitor, is in clinical development for AML and solid tumors. PoC with strong clinical activity in combo with azacitidine in a Phase II in unfit AML patients, and encouraging signals in 2L-ED-SCLC. Two ongoing trials in R/RFlt3mut+ AML and, SCLC and preparing a new trial in SCLC.

Pioneering development of epigenetic drugs in CNS with vafidemstat, a safe LSD1 inhibitor. Positive results reducing aggression in a Phase IIa basket trial in psychiatric patients. Two Phase IIb trials: One in borderline personality disorder fully recruited  and the other in schizophrenia actively recruiting. Also launching a CNS personalized medicine program, starting with a Phase I/II trial in Kabuki syndrome.

www.oryzon.com/

OSE Immunotherapeutics
[EURONEXT: OSE​]

OSE Immunotherapeutics is a clinical-stage and public biotech company focused on developing and partnering First-In-Class immunotherapies to control the immune system for immuno-oncology and immuno-inflammation.

Five clinical assets: 
• Tedopi® (immunotherapy activating tumor specific T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is the Company’s most advanced product; positive results from the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in secondary resistance after checkpoint inhibitor failure. Confirmatory pivotal phase 3 in preparation. Other Phase 2 trials, sponsored by clinical oncology groups, of Tedopi® in combination are ongoing in solid tumors.
• OSE-127 - lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor); ongoing Phase 2 in Ulcerative Colitis (sponsor OSE Immunotherapeutics); ongoing preclinical research in leukemia.
• OSE-172/BI 765063 (anti-SIRPα monoclonal antibody on CD47/SIRPα pathway) developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Phase 1 dose escalation results in monotherapy and in combination, in particular with anti-PD-1 antibody ezabenlimab; international Phase 1b ongoing clinical trial in combination with ezabenlimab alone or with other drugs.
• FR-104/VEL-101 (anti-CD28 monoclonal antibody): developed in partnership with Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1/2 in renal transplant (sponsor Nantes University Hospital); Phase 2 under preparation.
• OSE-279 (anti-PD1): ongoing Phase 1/2 in solid tumors or lymphomas.

Two innovative Research platform:
• BiCKI® platform is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. BiCKI-IL-7 is the most advanced BiCKI® candidate targeting anti-PD1xIL-7.
• Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO and immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb) is the most advanced candidate generated by the platform, with the potential to resolve chronic inflammation by targeting Neutrophils and inflammatory Macrophages.

www.ose-immmuno.com

Preci LLC

Preci aims to bridge the gap between animal testing and the outcome of the clinical trials.

Preci provides high-quality services in creation of primary human tissue-based assays. Our projects start with the assembly of the patient cohort, continue towards creation of the living 3D disease model and assay development. In this way, agnostic towards any particular biological technology, estimating only success rate data, we extract the prognosis of drug activity in humans. Our platform is scalable towards 100s of donors in single or multiple indications. All of our work is empowered by the wide clinical network, which ensures ethical collection of samples and patient data, needed to fulfil the particular project.

www.preci.bio

Teitur Trophics

Teitur is a Danish biotech company, founded on research from Biomedicine at Aarhus University. The company was established in 2020 with a convertible loan from BioInnovation Institute (“BII”) in Copenhagen, Denmark.
​
The company is founded by Simon Molgaard, Anders Dalby, Mathias Ollendorf and Simon Glerup and is supported seasoned advisors and a board of pharmaceutical industry veterans and by world class scientific experts in the field of neurodegenerative diseases.

In March 2023, Teitur announced the completion of a €28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest. The proceeds will enable Teitur to progress its lead drug candidate, TT-P34 into clinical development, including a Phase 1b clinical study in neurodegenerative diseases.

www.teiturtrophics.com/

Vaccentis AG

Vaccentis AG is a Zurich-based company focused on the biotech and pharmaceutical sector. All research, production and sales activities of the are carried out by two highly specialised subsidiaries, VCC MEDICAL and FBM-Pharma, which focus on special methods of individualised medicine. The rights to manufacture the medicines and therapies are held by Vaccentis AG.

www.accentis.com/

10-minute presenters

AATec Medical GmbH

AATec Medical GmbH is a biotechnology company developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of inflammatory diseases, virus infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-of-concept clinical trial with the first product candidate ATL-105 for inhaled application in respiratory diseases. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization.

www.aatec-medical.com

Akribion Genomics AG

Akribion Genomics develops a revolutionary, genetically-programmable and new therapy class for oncology, using novel nucleases, causing programmable cell depletion via RNA biomarker recognition. The nuclease can target a wide variety of cancer indications defined by genetic make up of patients and can also be applied beyond oncology.

The nucleases are protected by a strong IP position with FTO and the key patent granted in September 2023.

The technology had initially been developed within and the company is a spin out of BRAIN Biotech, a stock listed industrial Biotech player that focuses on industrial applications.

www.akribion-genomics.com/

AmacaThera Inc.

​AmacaThera is a clinical stage company focused on the commercialization of a hydrogel platform for sustained drug release. AmacaThera's propriety technology can be combined with therapeutic agents to form a product, which will localize the therapeutics to the injection site to improve the duration of action when injected into a tissue.  AmacaThera’s hydrogel platform is compatible with a wide range of therapeutics and can sustain release from a few days up to a month.  AmacaThera has shown applicability to a wide range of therapeutics from small molecules to growth factors and is seeking investment and collaborations to develop additional applications.

www.amacathera.ca

Amarna Therapeutics B.V.

Amarna Therapeutics has developed a unique, non-immunogenic viral platform named SVec, derived from the macaque polyomavirus Simian Virus 40 (SV40), to deliver transformative, potentially curative gene therapies for a range of rare and prevalent diseases, specifically hemophilia B and type 1 diabetes. We have some very exciting positive results in various in vivo animal models and are currently discussing with FDA the best way forward into the GLP-Tox and FiH studies.

Our SVec platform offers significant benefits over AAV.  While SVec has a similar loading capacity to AAV, SVec candidates are 100-fold more potent than AAV and, furthermore, enable drug redosing owing to the non-immunogenic nature of SVec.

We are actively seeking additional investors to join our €30M Series A to advance our lead programs to clinical proof of concept, that will not only address the redosing potential of SVec, but will also validate the technology for wider application. We would welcome the opportunity to introduce you to the novel gene therapy platform and to tell you more about our fundraising plans.

www.amarnatherapeutics.com

Amyl Therapeutics

Amyl therapeutics develops a breakthrough platform of fusion proteins for the treatment of amyloid mediated diseases: amyloidosis, neurodegenerative diseases and others.
​
www.amyltx.com/

Atamyo Therapeutics SAS

Atamyo Therapeutics is a clinical-stage biopharma focused on the development of a new generation of effective and safe gene therapies for muscular dystrophies and cardiomyopathies.

A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon.

Atamyo has a clinical-stage pipeline with first-in-class vectors which include new capsids, new promoters, and organs-detargeting technologies:
- ATA-100 is in phase 1b/2b in LGMD-R9/LGMD2I associated to deficiencies in the protein FKRP;
- ATA-200 is at IND stage for LGMD-R5 related to deficiencies in γ-sarcoglycans;
- ATA-300 is in IND-enabling studies and targets LGMD-R1/ LGMD2A or calpainopathy;
- The cardiomyopathy programs pursues several targets in Dilated Cardiomyopathies;

Atamyo’s seasoned management has a unique expertise in developing biotech products from Research to late stage clinical development:
- Stephane Degove, its CEO, is a biotech entrepreneur with 25 years’ experience in pharma/biotech and strategy.  
- Isabelle Richard, PhD, its Chief Scientific Officer, heads the Muscular Dystrophy department at Genethon and a pioneer in the research on gene therapy targeting muscular distrophies.
- Dr Sophie Olivier, its Chief Medical Officer, has extensive clinical development experience in large and small pharma organizations and has overseen multiple regulatory interactions with both the FDA and the EMA, particularly in regard to pediatric development and rare diseases.
- Catherine Cancian, its Chief Technical Officer, has 25 years CMC development in biologics, including gene therapy.

The name of the company is derived from two words: Celtic Atao which means “Always” or “Forever” and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments.

www.atamyo.com

Biomunex Pharmaceuticals

Biomunex is a biopharmaceutical company focused on providing differentiated immuno-therapeutics through the discovery and development of bi- and multi-specific antibodies, created from its proprietary BiXAb® platform. Biomunex is developing a disruptive biological approach, the so-called MAIT-engagers, that redirect MAIT cells to kill cancers which will become a true game changer in the field of cancer immunotherapy.​

www.biomunex.com

Biotx.ai, GmbH

biotx.ai's causal AI mimics clinical trials in human genetic data.

Internally this has led to 3 drugs, each with high probability of success, now in clinical development.

www.biotx.ai/

Bioxodes SA

Bioxodes, a phase 2a clinical stage Biotech company developing a first-in-class drug candidate, Ir-CPI, for the prevention of thrombosis and neuroinflammation in acute hemorrhagic stroke patients.

Intracerebral hemorrhage (ICH), is a devastating cerebrovascular orphan disease leading to high morbidity and mortality.

Our drug candidate has the potential to reach the market by end 2027 - early 2028 thanks to potential Orphan Drug Designation (application ongoing). To date, no specific or effective treatment approaches are available during the first 72 hours of onset.

bioxodes.com/

CellProthera SAS

CellProthera is a clinical-stage biotech developing innovative stem cell therapies. Preliminary data from its Phase I/IIb show promising results of its lead product candidate ProtheraCytes®. The therapy aims at repairing damaged heart tissues following a severe myocardial infarction, preempting the deleterious occurrence of heart failure. Its cellular product, based on unique production methods and a protected technology, has the potential to reperfuse and salvage even the deepest layers of the heart through the development of new blood vessels. The company’s technology has been tested in other indications, such as ischemic stroke, with successful preclinical results.​

www.cellprothera.com/en/home/

Delta 4 GmbH

Delta4 is an AI Drug Discovery Biotech Company with a focus on Indication Expansion.

By utilizing Hyper-C, a proprietary artificial intelligence powered platform, Delta4's team detects relationships between drugs with a known safety profile and diseases with unprecedented speed.

www.delta4.ai

eleva GmbH

Eleva uses its proprietary moss cell culture (Bryotechnology) to produce highly complex and difficult to express biopharmaceuticals with optimized human-like glycosylation. The first moss-based protein has been successfully tested in a clinical trial.

RPV-001: recombinant alpha-galactosidase enzyme for the treatment of Fabry disease as an enzyme replacement therapy, clinical safety confirmed in phase I study.

CPV-104: extensive pre-clinical testing completed (dry AMD, PNH, C3G, ANCA, lupus nephritis), toxicity studies ongoing, potential treatment for multiple complement indications.

Bryotechnology provides a highly robust production platform that can be run in state-of-the-art bioreactors over a wide range of temperature and pH conditions. Stability, consistency, and homogeneity of N-glycosylation are remarkable and less affected by process conditions and scale. The GMP-compliant system is easily transferable and is known for its batch-to-batch stability and safety. By using simple culture media and avoiding virus filtration systems, even challenging proteins can be produced in a cost-effective manner. The platform is available for out-licensing.

The Eleva team is eager to tackle the most challenging molecules. We welcome your enquiries regarding strategic partnerships, collaborations, co-development, and licensing of RPV-001, CPV-104 and the Bryotechnology platform.

www.elevabiologics.com

Engimmune Therapeutics AG

Engimmune Therapeutics is developing next-generation T cell receptor (TCR)-based therapies to address unmet patient needs in oncology and immune-mediated diseases.
​
We couple high-throughput data generation and artificial intelligence (AI) to accelerate soluble TCR drug development.

www.engimmune.com/

GliaPharm SA

GliaPharm is a Swiss biotechnology company that develops treatments for neurological and psychiatric disorders.​

www.gliapharm.com/

Herantis Pharma Plc
[​HEL: HRTIS]

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The ongoing Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. Top-line data is expected in Q4-2023. 

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

www.herantis.com/

Intract Pharma Ltd.

Intract is leveraging it's oral biologics delivery platform to create a best-in-class pipeline of orally delivered antibody medicines in immuno-inflamamtory indications. Lead asset is an oral IL12/23 inhibitor mAb currently in preclinical for treatment of moderate to severe ulcerative colitis.

www.intractpharma.com

leon-nanodrugs GmbH

leon-nanodrugs GmbH is a pharmatech company specializing in the development of devices for the encapsulation of genetic material and other active substances into nanodrug carriers, such as lipid nanoparticles (LNPs). The Munich-based private company builds its innovative solutions based on its proprietary FR-JET Technology, enabling pharma companies and small biotechs as well as CDMOs to optimize nanomedicine manufacturing and take full advantage of the significant progress being made in advanced therapies. LEON's GMP-compliant, aseptic devices NANOme®  and NANOus®  increase efficiency in the production of nano drug carriers and are suitable for both clinical-scale and commercial production. Our NANOlab® device enables process parameter screening while easing and de-risking scale-up from smaller to larger quantities.

leon-nanodrugs.com/

LIfT BioSciences Ltd.

LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity.

The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess. 

The company is working with a range of pharmaceutical license partners to develop a portfolio of CAR-IMAN cell therapies to deliver complete remission across all solid tumours before the decade is out. LIfT BioSciences was founded by Alex Blyth following the death of his mother to pancreatic cancer.

Technology:
Immuno-Modulatory Alpha Neutrophil progenitors (IMANs) produced from iPSCs or HSCs using our N-LIfT Platform

Stage:
Pre-clinical work completing, IND filing H2,2023

Focus:
Solid Tumours with high unmet medical need, starting with SCC-NSCLC, PDAC, HNSCC, UCC

Patents:
2016 Filing Granted, 6 Patents with FTO 

Current Raise:
£25m+ Series A. Pharma license discussions underway.

Recent Achievements:
- Successful production from iPSCs and GMP ready production from HSCs at 10L
-  Increase T-cell and NK cancer killing 250% in Lab-on-chip tumour model 
- Unmodified IMANs shows comprehensive solid tumour organoid killing (superior to Keytruda & Abraxane) in NSCLC, PDAC
-  HER-2 CAR IMANs increase cancer cell killing x5 over the already potent unmodified

LIfT IMANs have preclinical validation of all of the characteristics required to overcome the challenges to achieving sustained remission in solid tumours.

www.liftbiosciences.com/

On/Off Therapeutics SAS

On/Off Therapeutics is a start-up company at IND-enabling stage, developing a breakthrough technology published in Nature Biotechnology, which enables the expression of genes to be controlled in vivo over time. The technology, called Nutrireg®, is based on the activation of a proprietary artificial promoter by a specific, also proprietary, dietary supplement. This technology enables the on-demand expression of a transgene previously introduced into the organism (via a viral or non-viral vector), without the use of any potentially toxic activator. It is thus possible to control in situ the production of an mRNA (and therefore of a peptide or protein), or of an siRNA or shRNA, very rapidly and in a totally reversible way, with no leakage. A Phase I clinical trial in healthy volunteers showed that Nutrireg® can be activated and deactivated in 2-3 hours.

This technology has therefore a wide range of applications, including in situ biosynthesis of therapeutic peptides with very short half-lives, making them difficult to administer by the iv route, or of therapeutic peptides whose 24-hour in vivo biosynthesis after transfection by gene therapy could be deleterious. Furthermore, preliminary results have shown that controlled activation of certain transgenes can be very useful in cell therapy applications to activate or deactivate certain functions (CAR-T, CAR-NK, etc.).

Our strategy is dual: (i) to develop as clinical proof of concept a first product (metastatic colorectal cancer with liver metastases), and (ii) to conduct an active business-development activity with pharmaceutical companies whose candidate-drugs (peptides or nucleic acids) would benefit from our technology.

The Sachs Biotech Forum is the first event in our road show intended to meet investors and representatives from pharma companies scouting for breakthrough technologies.

www.on-off-therapeutics.com

PDC*line Pharma SA

Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells (PDC*line). PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC*line Pharma focuses on the development of PDC*lung01, a candidate for Non-Small-Cell Lung Cancer (NSCLC) currently in phase I/II trials, and PDC*neo with neoantigens in preclinical development. The company has a staff of 32, with an experienced management team. It has raised close to €56M in equity and non-dilutive funding. In March 2019, PDC*line Pharma granted an exclusive license to the LG Chem Life Sciences company in South Korea and an exclusive option in other Asian countries, for the development and commercialization of the PDC*lung01 cancer vaccine for lung cancer. The total deal is worth €108M, plus tiered royalties on net sales in Asia.​

www.pdc-line-pharma.com/

PerioTrap Pharmaceuticals GmbH

PerioTrap is an emerging Biotech company developing novel microbiome-based treatments in oral care. We focus on Pathoblocker approaches that solely reduce virulence to harness efficacy while minimizing bacterial resistance. Our goal is to prevent current and future oral care gaps with more efficient products, specifically in periodontology.​

periotrap.com/

ProVascTec Ltd​

ProVascTec’s mission is to positively impact the lives of patients suffering from cardiovascular complications.

ProVascTec is a preclinical stage device-driven cell therapy company, leveraging the paracrine mechanism of stem cells to induce the growth of a novel vascular system, creating a natural bypass around arterial occlusions in the peripheral vascular system, specifically below the knee. Our investigational off-the-shelf stem cells are combined with a proprietary land patent-protected local delivery system, suitable for integration into well established percutaneous delivery procedures.

www.provasctec.com/

Resistell AG​

Resistell AG is a clinical stage company developing the world’s fastest Antibiotic Susceptibility Testing (AST) Platform. Resistell has a CE IVD certified AST in bloodstream infections (BSI) with a time-to-result of 4 hours, tested on 260 patients in two clinical studies across three hospitals (Lausanne, Switzerland; Madrid, Spain; and Innsbruck, Austria). The method shows over 95% accuracy with the gold standard for AST. The 2nd generation device and pre-clinical data enabling an ultra-rapid AST of only 2 hours are already available. In addition to the diagnostic product, Resistell offers a globally certified research device and disposable kits for exploring new applications that we have recently launched on the market.

Resistell AST is based on a disruptive, proprietary nanomotion technology platform for measuring induced metabolic changes in living cells combined with machine learning for the development of classification algorithms. The technology is developed in-house by a cross-functional team (30 FTE) of microbiologists, engineers, and data scientists. The company is ISO 13485 certified.

www.resistell.com/

SiSaf Ltd.

SiSaf is an RNA delivery and therapeutics company. Its proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon.

The company is developing a pipeline of RNA therapeutics for rare genetic disorders and is maximizing the potential of its technology through partnerships.

Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital-backed private company. Headquartered in Guildford, UK, it has fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.

www.sisaf.com/

Thermosome GmbH

Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach that allows for significantly increased local drug concentrations and improved tumor penetration to achieve improved clinical treatment efficacy. The lead candidate THE001 is a thermosensitive formulation of doxorubicin being developed in soft tissue sarcoma, an indication with high unmet medical need.

www.thermosome.com/

TOLREMO Therapeutics AG

TOLREMO therapeutics’ mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound, TT125-802, is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the durability of established treatments. By stopping cancer drug resistance as it emerges, we aim to surmount a universal challenge for current and future targeted therapies for lasting patient benefit.​

www.tolremo.com

WMT AG​

WMT develops small molecule drugs to treat late stage solid cancers. We have evolved a drug candidate, B-306, with decent activity in various xenograft and syngeneic tumor models. B-306 induces the Intracellular Stress Response (ISR) which results in a cellular lockdown of protein translation and metabolism. This changes the tumor microenvironment and has the potential to break resistance of late stage solid cancers against classical chemotherapy as well as the chance to improve the efficacy of immunotherapies.​

www.wm-therapeutics.com

Ymmunobio AG

Ymmunobio (YB) is a Swiss preclinical stage oncology biotech company focused on fighting gastro-intestinal cancers. YB is developing novel class and first in class antibodies. The first compound, a novel class of CEACAM1/5 antibodies (YB-200) increases the efficiency of the immune response in clearing cancer cells including an increase in anti-tumor immunity. The second, an NPTXR antibody (YB-800) is a first in class antibody binding on NPTXR-positive cancer cells and not affecting healthy tissue. The YB-800/NPTXR conjugate gets internalized and ADC development is ongoing. 

Ymmunobio has raised CHF 1.3 Mio to date by founders and private individuals and is now actively pursuing capital investment of CHF 8 Mio to move the development of the lead compound forward to IND approval stage. 

YB has assembled a team of experts in oncology drug development and renowned scientific leaders in the field of CEACAM & NPTXR research.
​
​www.ymmunobio.com/

rising biotech stars

Adoram Therapeutics SA

Adoram Therapeutics is a discovery-to-early-clinical Swiss-based start-up, discovering small molecule therapies with a disruptive ‘allosteric’ mode of action, that provides both improved efficacy and safety compared to conventional drugs.

Our primary asset is a cancer immunotherapy to treat many types of solid tumors. Additional novel assets for CNS & inflammatory indications are in the hit-to-lead phase.

To further expand our pipeline, a sensitive screening assays that outperforms industry standard methods can be used to identify allosteric drug hits that modulate ‘GPCRs’, the largest class of human receptors.

We are currently securing funding to move towards the clinic with our lead cancer immunotherapy asset, and complete the preclinical proof-of-concept with the secondary assets – innovative allosteric drugs to treat inflammatory and neurodegenerative diseases.

adoram.ch

Allogenica

Allogenica is a Lyon-based biotechnology company specialized in the development of an emerging class of cancer therapy, called CAR-T cells (Chimeric Antigen Receptor T-cells). Allogenica has developed a bioproduction platform that relies on the manipulation of hematopoietic stem cells and their derivatives with the aim of developing allogenic "off-the-shelf" CAR-T cells. Allogenica will offer the next-generation cancer treatment ready to use, at low cost and safer than current treatments, in order to treat all patients who need it.

AtG Therapeutics

AtG is an early-stage pre-clinical biotech company with HQ in Barcelona, Spain, established in 2022 as a spin-off of two leading cancer centers in the country.

AtG focuses on Overcoming Tumor Adaptation, which is critical to advance in our fight against cancer, as this is a dynamic disease. Our approach is to develop inhibitors against adaptation vulnerabilities coupled with patient selectors that will be key in addressing this dynamism.

AtG has a Target Discovery Platform (TACTIC - Tumor Adaptation Target Identification) that has allowed us to generate multiple targets of interest to date, including TA-1, the focus of our current development efforts.
​
TA-1 is a pro-tumor enzyme that has been identified as a resistant mechanism to anti-angiogenic therapy, a very large established market confirmed to stay by top key opinion leaders that have reviewed the AtG opportunity. 
However, TA-1 has also shown to be over-expressed in many untreated tumor types, hence the opportunity of making an impact with an inhibitor against this target is very large.

We are currently developing a first in class intracellular inhibitor against TA-1, aiming to have a pre-clinical candidate selected by end of 2024.

www.atgtx.com/

CaSRevolution S.r.l.

CaSRevolution identified a novel upstream therapeutic target for a disease-modifying approach against Alzheimer’s disease: in fact, pharmacological inhibition and genetic manipulation of its new target - which is promising also because it can be modulated with a small molecule - prevent neurodegeneration in disease-relevant in vitro & in vivo models.

The management team and the board of directors have broad experience in company creation & successful exits, neurodegeneration, and drug development.

It plans to develop First-in-Class compound(s) to treat early-stage AD, MCI, and dementia due to AD. Therefore, it designed a capital-efficient lead-to-candidate drug discovery plan to be ready for an Investigational New Drug (IND) application on the best candidate within 3 years.

casrevolution.com/

FimmCyte AG

FimmCyte is a women’s health company with the vision to create tailored women’s health therapeutics to drive equality and prosperity. FimmCyte’s lead program, FMC2, is a first-in-class disease-modifying treatment for endometriosis, a painful and debilitating condition that affects one in every ten women.​
​
www.fimmcyte.com/

InCephalo Therapeutics​

InCephalo was founded in 2021, in Basel, Switzerland, as a UZH spinoff focusing on new therapies for disorders in the CNS.

At InCephalo Therapeutics AG, we aim to add brain cancer to the list of curable diseases. We believe that potent immunostimulation, contained in the tumour microenvironment, needs to become a crucial part of today's and future therapeutic interventions. For this, we develop proprietary compartment-locked cytokine therapies with high local tissue retention and fast systemic degradation for a maximised therapeutic index. Despite our project's mature and ambitious nature, we are convinced it could disrupt today’s treatment practices for brain cancer patients.

Additionally, our proprietary compartment-locked technology, which retains locally applied biologics in the brain, can be expanded into many other CNS diseases. Therefore opening the door for many more therapeutic solutions in the CNS space.

www.incephalo.com

iPSirius

iPSirius SAS is an immuno-oncology firm focused on developing IPVAC 1.0, a novel therapeutic cancer vaccine. Leveraging the antigenic overlap between induced pluripotent stem cells (iPSCs) and cancer stem cells (CSCs), iPSirius aims to combat relapse and metastatic progression in cancer patients. The company, a spinout from Inserm and Saclay University In Paris, is at the forefront of utilizing iPSCs as a delivery system for cancer targets. By training the immune response on CSCs, iPSirius strives to overcome the limitations of current therapies in combating metastases and the emergence of resistance.

iPSirius is dedicated to revolutionizing cancer treatment through the development of IPVAC 1.0. The company's initial focus is on non-small-cell lung cancer (NSCLC), where IPVAC has the potential to break up metastatic dissemination. With promising results in animal studies and the inclusion of multiple antigens, IPVAC shows promise for addressing various cancer types.

iPSirius has received grant funding USD$2.4M, mainly from the European Innovation Council but also French Private Investment Bank BPI France. Additional tranches of USD$2M or more available subject to clinical milestones being reached. The company is actively seeking series A funding to advance IPVAC 1.0 into clinical trials. With a commitment to innovation and improving patient outcomes, iPSirius aims to bring transformative therapies to the field of cancer treatment.

iPSirius has built up an extensive patent portfolio around IPVAC 1.0, and is interested in talking with cell therapy companies considering adding IPVAC 1.0 to their clinical program as a de-risking measure against the production of more complex living cell therapy products.

www.ipsirius.com/

LaRive Bio AG

LaRive Bio AG, a Swiss-based organization, is dedicated to accelerating the development of therapeutic solutions for some of the most challenging chronic conditions. Our business model is centered on a platform for acquiring, developing and divesting molecules from and to biotech companies. By utilizing our core drug and business development expertise, we partner with innovative biotech groups to lead promising candidates through Phase I / II and potentially Phase III studies and build a business plan for successful divestment or out-licensing.

Priority is given to commercially attractive drug candidates that qualify for accelerated regulatory pathways.

Led by a highly experienced team with a proven track record in biopharmaceutical and business development sectors, LaRive Bio initiates a CHF 10 million raise to launch a Phase I trial for a novel molecule for Multiple Sclerosis.

lavie-bio.com/

​Modiblast Pharma GmbH

Modiblast Pharma GmbH is ready to advance into the clinical development phase with novel Dendritic Cell Therapies for liquid cancers. The focus is to target the core issue in acute myeloid leukemias (AML) and Myelodysplastic Syndromes (MDS): the extremely high rate of relapses after successful initial therapy.

The Modiblast approach (3 patents granted) combines immunomodulators to induce blast cells to differentiate into leukemia-specific dendritic cells (DCleu) in the patient. This triggers both innate and adaptive immune cells in blood and tissue to kill remaining or recurring blasts and generates memory cells.

Contrary to e.g. CAR-T there is no need to identify and select specific target molecules. And it doesn’t require complicated and expensive ex vivo cell extraction and preparation procedures and GMP facilities.

Our long-term goal is to provide an easy-to-use self-administered drug that can stabilize remissions or halt progression of the diseases. This therapy may also normalize thrombocyte/neutrophil counts.

The next step of clinical development is a Phase 1a/2b study which recently has passed BfArM scientific advice.

www.modiblast.com/

Mysthera Therapeutics AG

Mysthera Therapeutics AG was founded in Basel, Switzerland by Forty51 Ventures in 2023. Pursuing a first-in-class therapeutic approach, Mysthera plans to reshape the treatment landscape for autoimmune disease. PIM kinase inhibition uniquely and selectively modulates immune cell function in multiple lineages associated with complex disease.  The company’s pipeline includes pre-clinical stage, PIM kinase inhibitors in-licensed from Inflection Biosciences Ltd.

www.mystheratx.com

Odimma Therapeutics

We are a startup (creation 2017) from Strasbourg developing a proprietary personalized and powerful immunotherapy platform based on the disruptive technology of Synthetic DNA and advanced algorithms .  We aim to treat patients suffering form hard to treat cancer in a shortened timeframe (8 weeks) .We have strong POC and secured GMP supply chain. We aim for First in man clinical trial end of 2023.​

www.odimma-therapeutics.com/

​On/Off Therapeutics SAS

On/Off Therapeutics is a start-up company at IND-enabling stage, developing a breakthrough technology published in Nature Biotechnology, which enables the expression of genes to be controlled in vivo over time. The technology, called Nutrireg®, is based on the activation of a proprietary artificial promoter by a specific, also proprietary, dietary supplement. This technology enables the on-demand expression of a transgene previously introduced into the organism (via a viral or non-viral vector), without the use of any potentially toxic activator. It is thus possible to control in situ the production of an mRNA (and therefore of a peptide or protein), or of an siRNA or shRNA, very rapidly and in a totally reversible way, with no leakage. A Phase I clinical trial in healthy volunteers showed that Nutrireg® can be activated and deactivated in 2-3 hours.

This technology has therefore a wide range of applications, including in situ biosynthesis of therapeutic peptides with very short half-lives, making them difficult to administer by the iv route, or of therapeutic peptides whose 24-hour in vivo biosynthesis after transfection by gene therapy could be deleterious. Furthermore, preliminary results have shown that controlled activation of certain transgenes can be very useful in cell therapy applications to activate or deactivate certain functions (CAR-T, CAR-NK, etc.).

Our strategy is dual: (i) to develop as clinical proof of concept a first product (metastatic colorectal cancer with liver metastases), and (ii) to conduct an active business-development activity with pharmaceutical companies whose candidate-drugs (peptides or nucleic acids) would benefit from our technology.

The Sachs Biotech Forum is the first event in our road show intended to meet investors and representatives from pharma companies scouting for breakthrough technologies.

www.on-off-therapeutics.com

PRAMOMOLECULAR GmbH

PRAMOMOLECULAR is an early-stage biopharmaceutical company developing anti-cancer drugs based on proprietary self-delivering siRNAs. Our self-delivering siRNAs are particularly good at crossing the cell membrane of non-hepatic tissues such as lung, heart, pancreas, or colon in vivo. This enables efficient gene silencing in these target tissues.
​
PRAMOMOLECULAR is currently working on lead optimization of drug candidates against cancers in target tissues caused by oncogenic KRAS mutations. We also offer the delivery technology to other developers of therapeutic oligonucleotides for selected applications.

www.pramomolecular.com

Reconnect Labs AG

Reconnect Labs is a Swiss, clinical stage pharmaceutical company developing Regenerative Therapeutics™ for mental health at the forefront of neuroscience and precision psychopharmacology.

Led by KOL neuroscientists from the University of Zurich Psychiatric University Clinic and a seasoned team of pharmaceutical executives, Reconnect Labs has developed a disease modifying new treatment paradigm that combines regenerative molecules with psychotherapy. The therapeutic approach is regenerative both biologically and psychologically, and is administered over several treatments rather than on an on-going basis. In clinical trials, this new paradigm has shown breakthrough efficacy (88% response) with effects sustained up to 1 year for some patients.

www.reconnect-labs.com

StemSight Oy

StemSight develops off-the-shelf cell therapies for corneal blindness using induced pluripotent stem cells and biomaterials. Using the same raw material stem cells and biomaterials, we are pursuing a platform which first aims to treat a severe rare disease limbal stem cell deficiency, later expanding to corneal endothelial dystrophies - the underlying disease for half of the corneal transplantations done today.​

www.stemsight.fi/

TheraOnco

Even today, one of the most critical issues is the capability to target all tumour cells present within a cancer. The proprietary and patented platform that TheraOnco has developed has the potential to bridge this gap. TheraOnco was co-founded in 2022 by Dr. Sam Dukan, a serial entrepreneur / visionary inventor, and Didier Noel, experienced in technology transfer and startup financing. After preliminary validation of its disruptive cell labelling-mediated platform targeting cancer, TheraOnco revealed positive preclinical toxicity and efficacy results in animals for its leading candidate metabolite analogue. Our proprietary platform is based on localizing preferentially bio-orthogonal function (-N3 function) in macromolecules present in tumour cells via internal assimilation and metabolization of a non-toxic clickable natural pentose analogue, exclusively through the pentose phosphate pathway (over-expressed in almost all tumour cells, as a tumour hallmark). Using this process, we may render all tumour cells “identical” to whatever they were before the assimilation of our metabolic analogues. Using bio-orthogonal click chemistry, we then covalently link these to all kinds of clickable molecules (fluorochrome, antitumour agents, antibodies, liposomes….) allowing us to preferentially localize or destroy tumour cells. Today, we have (i) substantial proof of concept of our platform in vitro, with more than 30 tumour cell lines preferentially labeled, and (ii) preliminary proof of concept for pancreatic and lung (NSCLC) cancer in animals. In summary, our proprietary platform allows artificial antigens to be inserted onto all tumour cell surfaces, providing enhanced efficacity of all antitumour agents and decreased side effects. Although, as for ADC, there is a local concentration of antitumour agent, our approach is radically different since it is agnostic of the type of cancer and is much cheaper (with regards to development time and cost). More importantly, within a tumour, all tumour cells will be targeted. ​

www.theraonco.com/

VIRTUAL PRESENTERS:

10-MINUTE PRESENTERs:

​Brenus Pharma

Brenus Pharma is a private French biotech company working to address a huge unmet need: 90% of solid tumor patients face relapse due to current limitations in treatment, such as limited and static targets that fail to anticipate tumor evolution and the inefficient education of the immune system, leading to treatment resistance and disease progression.

Brenus has developed its proprietary platform: ""Stimulated Tumor Cells"" (STC), which mimics patient relapse conditions in vitro, resulting in a multi-specific tumoral signature validated by proteomics analysis.

This therapeutic vaccine approach educates the immune system to recognize a broader and higher quality range of tumor antigens, thus anticipating tumor evolution and avoiding progression and relapse from the early stage of treatment.

The STC platform has produced Brenus' lead candidate, STC-1010, a vaccine for colorectal and gastro-intestinal cancer patients, which has demonstrated high potential for clinical efficacy. It is backed by a strong preclinical package and toxicity study and has been pre-validated by the FDA and EMA for use in the first line setting. With strong GMP manufacturing capabilities, Brenus anticipates launching its first clinical study in 2024 and expects to deliver safety and efficacy data by 2025.

Brenus boasts a robust IP Strategy protecting both the platform and products via a platform patent granted in key countries and additional product patents based on multi-omics characterization.

This unique technology and strong IP protection provide limitless potential to generate first-in-class immunotherapies and cancer vaccines for further indications, controlling industrial scale-up costs.

Brenus is committed to facilitating a personalized approach using organ-on-chip developments, as well as pursuing its innovative positioning through the integration of AI deep-learning models; to accelerate the platform drug-discovery process and deliver strong candidates that give patients a chance to fight against diseases with still low survival rates.

www.brenus-pharma.com/